Posted by Michael Wonder on 16 Feb 2024
Sibeprenlimab received US FDA breakthrough therapy designation for the treatment of immunoglobulin A nephropathy
16 February 2024 - Otsuka and Visterra announce that the US FDA has granted breakthrough therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin nephropathy (IgAN; Berger's disease).
Sibeprenlimab is a humanised monoclonal antibody that blocks the action of B cell growth factor, cytokine APRIL (an acronym for a proliferation-inducing ligand), which plays a key role in the development and progression of IgAN.
